Monclonal B-cell Lymphocytosis; clinical and biological characteristics

Withdrawn

• Conditions: chronic leukemia; Monoclonal B-cell Lymphocytosis; 10024324

• Registration Number: NL-OMON34393
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

All patients over the age of 18 years who were diagnosed with MBL or CLL ever since March 2001 are eligible for the study.

Exclusion Criteria

Psychiatric disease or inability to give informed consent

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Characterisation of cell surface markers of MBL patients compared to an<br /><br>age-matched control group from general population and to CLL patients.<br /><br><br /><br>- Gene expression levels of MBL patients compared to normal B-lymphocytes and<br /><br>to CLL patients. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Descriptive analysis of incidence of infections and antibiotics usage in<br /><br>patients with MBL.<br /><br><br /><br>- Characterisation of cell surface markers of non-progressive MBL patients<br /><br>versus progressive MBL patients<br /><br><br /><br>- Characterisation of gene expression levels of non-progressive MBL patients<br /><br>versus progressive MBL patients. </p><br>